Literature DB >> 18848855

The global impact of vaccination against hepatitis B: a historical overview.

Alessandro R Zanetti1, Pierre Van Damme, Daniel Shouval.   

Abstract

Hepatitis B virus (HBV) infection is a world wide public health problem of major concern. HBV infection may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma (HCC). Vaccination is the most effective measure to control and prevent hepatitis B and its long-term serious sequelae on global scale, both in terms of cost-effectiveness and benefit-cost ratios. According to the WHO recommendations, universal vaccination has been currently implemented in 168 countries world wide with an outstanding record of safety and efficacy. The effective implementation of such programmes of vaccination has resulted in a substantial decrease in disease burden, in the carrier rate and in hepatitis B-related morbidity and mortality. A future challenge is to overcome the social and economic hurdles which still hamper the introduction of hepatitis B vaccination on a global scale.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848855     DOI: 10.1016/j.vaccine.2008.09.056

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  134 in total

Review 1.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

Review 2.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

Review 3.  Viruses and human cancer: from detection to causality.

Authors:  Ronit Sarid; Shou-Jiang Gao
Journal:  Cancer Lett       Date:  2010-10-23       Impact factor: 8.679

4.  Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes.

Authors:  Masaki Kato; Susumu Hamada-Tsutsumi; Chiaki Okuse; Aiko Sakai; Nobuyuki Matsumoto; Masaaki Sato; Toshiyuki Sato; Mitsumi Arito; Kazuki Omoteyama; Naoya Suematsu; Kazuki Okamoto; Takanobu Kato; Fumio Itoh; Ryo Sumazaki; Yasuhito Tanaka; Hiroshi Yotsuyanagi; Tomohiro Kato; Manae Suzuki Kurokawa
Journal:  J Gastroenterol       Date:  2017-02-14       Impact factor: 7.527

5.  Criteria for hepatitis B virus screening and validation of blood components in Italy: the position of the SIMTI HBV working group.

Authors:  Claudio Velati; Laura Fomiatti; Lorella Baruffi; Vanessa Piccinini; Daniele Prati; Anna Reina; Andrea Lobbiani; Alessandro Zanetti; Luisa Romanò
Journal:  Blood Transfus       Date:  2011-07-21       Impact factor: 3.443

6.  Hepatitis B virus seroprevalence among Malawian medical students: A cross-sectional study.

Authors:  Froid Chipetah; Aaron Chirambo; Ednas Billiat; Isaac Thom Shawa
Journal:  Malawi Med J       Date:  2017-03       Impact factor: 0.875

Review 7.  Hepatitis B vaccination.

Authors:  Luisa Romanò; Sara Paladini; Cristina Galli; Giovanni Raimondo; Teresa Pollicino; Alessandro R Zanetti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

8.  Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation.

Authors:  Karen Kwei; Xiaoli Tang; Anna S Lok; Camille Sureau; Tamako Garcia; Jisu Li; Jack Wands; Shuping Tong
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

Review 9.  Bloodborne viral hepatitis infections among drug users: the role of vaccination.

Authors:  Fabio Lugoboni; Gianluca Quaglio; Paolo Civitelli; Paolo Mezzelani
Journal:  Int J Environ Res Public Health       Date:  2009-01-22       Impact factor: 3.390

10.  View and review on viral oncology research.

Authors:  Valeria Bergonzini; Cristiano Salata; Arianna Calistri; Cristina Parolin; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2010-05-24       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.